BRIEF published on 11/04/2024 at 11:51, 1 year 8 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 8 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 9 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 9 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 2 years ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 07/09/2024 at 20:45, 2 years ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
BRIEF published on 05/15/2024 at 11:20, 2 years 1 month ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 2 years 1 month ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 07/11/2026 at 02:50, 1 day 4 hours ago Alaska Energy Metals Reports on At-the-Market Equity Financing Program
Published on 07/11/2026 at 02:00, 1 day 4 hours ago Battery X Metals Presents Positive Preliminary Lithium-Ion Battery Rebalancing Trial Results Demonstrating Significant Estimated Driving Range Improvements and Accelerated Commercialization Progress of its Patent-Pending Lithium-Ion Battery Rebalancing Te
Published on 07/11/2026 at 02:00, 1 day 4 hours ago Discovery Energy Metals Announces Non-Brokered Private Placement Financing
Published on 07/11/2026 at 00:00, 1 day 6 hours ago Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010’s API
Published on 07/11/2026 at 04:00, 1 day 2 hours ago CUHK Achieves Top 20 Global Ranking in QS World University Rankings 2027
Published on 07/10/2026 at 18:40, 1 day 12 hours ago AFX Surpasses $1.1 Billion in Total Trading Volume, Highlighting Capital Efficiency in On-Chain Derivatives
Published on 07/10/2026 at 17:45, 1 day 13 hours ago WYF Launches Global AI Talent Compact at AI for Good Global Summit 2026
Published on 07/10/2026 at 17:14, 1 day 13 hours ago Form 8.3 - SAFESTAY PLC: Opening Position Disclosure
Published on 07/10/2026 at 18:00, 1 day 12 hours ago Half-year liquidity contract statement for CEGEDIM
Published on 07/10/2026 at 10:34, 1 day 20 hours ago Number of shares and voting rights - June 2026 (In French only)
Published on 07/09/2026 at 18:00, 2 days 12 hours ago Second-quarter 2026 activity: +7% (vs. Q2 2025)
